Lifecore Biomedical, Inc.: 5%+ holders

As of November 9, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Lifecore Biomedical, Inc. The largest reported stake is Legion Partners Asset Management, LLC's, at 17.3%. 9 filings are on record since July 17, 2025 (Schedule 13D/A, September 28, 2026).

Who owns Lifecore Biomedical, Inc. \de\?

Legion Partners, L.P. I also filed stake reports on 2 other companies ↓

Sell to companies like Lifecore Biomedical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-09-29 · Reporting person: Wynnefield Partners Small Cap Value, L.P. I · Sole voting: 2,405,090 · Shared voting: 0 · Sole dispositive: 2,405,090 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-29
• Filing 2026-09-28 · Reporting person: Legion Partners, L.P. I · Sole voting: 0 · Shared voting: 6,376,738 · Sole dispositive: 0 · Shared dispositive: 6,376,738 · SCHEDULE 13D/A, 2026-09-28
• Filing 2026-07-29 · Reporting person: BlackRock, Inc. · Sole voting: 1,988,535 · Shared voting: 0 · Sole dispositive: 2,010,546 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
• Filing 2026-07-02 · Reporting person: 22NW Fund, LP · Sole voting: 2,712,472 · Shared voting: 0 · Sole dispositive: 2,712,472 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-02
• Filed 2026-07-02 · Holder: Legion Partners Asset Management, LLC · Percent: 17.1% · SCHEDULE 13D/A

Lifecore Biomedical, Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-17. 4 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Lifecore Biomedical, Inc. and the warning signs.

See Lifecore Biomedical, Inc.'s free Snapshot Watch Lifecore Biomedical, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Lifecore Biomedical, Inc. and the records around it.

Lifecore Biomedical, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Legion Partners, L.P. I also filed stake reports on 2 other companies: NN INC (Aug 2026), Clear Channel Outdoor Holdings, Inc. (Jun 2026)
• 22NW Fund, LP also filed stake reports on 7 other companies: PhenixFIN Corp (May 2026), FARMER BROTHERS CO (May 2026), FOSTER L B CO (Apr 2026)
• BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)

Want the whole picture on Lifecore Biomedical, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Lifecore Biomedical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Lifecore Biomedical, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   10 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Lifecore Biomedical, Inc. by CUSIP 514766104 and gives its principal executive office as 3515 Lyman Boulevard, Chaska, MN 55318 (SCHEDULE 13D/A, 2026-09-29).

Source of funds (Item 3)

Item 3 is hereby amended and restated to read as follows: The Shares purchased by each of Legion Partners I, Legion Partners II and Legion Partners Holdings were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 4,084,268 Shares owned directly by Legion Partners I is approximately $33,506,562, including brokerage commissions.Legion Partners Asset Management, LLC, SCHEDULE 13D/A, 2026-09-28

Purpose of Transaction (Item 4)

Legion Partners Asset Management, LLC

Item 4 is hereby amended to add the following: On September 27, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lifecore Inc., a Delaware corporation ("Parent"), and Hazel Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent ("Merger Sub"). The Merger Agreement provides that, among other things, on the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. Under the terms of the Merger Agreement, each Share issued and outstanding immediately prior to the date and time that the Merger becomes effective (the "Effective Time"), excluding any Excluded Shares (as defined below), will receive $6.28 per Share in cash plus one (1) contingent value right per share (each, a "CVR") (collectively, the "Common Stock Merger Consideration"). Excluded Shares include Shares or Series A Preferred Stock held by the Issuer, Parent or Merger Sub, and Dissenting Shares. At the Effective Time, each share of the Series A Preferred Stock issued and outstanding immediately prior to the Effective Time, excluding any Excluded Shares, will be canceled and cease to exist and be converted into the right to receive an amount in cash per share of Series A Preferred Stock equal to the "Conversion Amount" as defined in Section 3 of the Certificate of Designations, Preferences and Rights …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-28; the filing has the rest

22NW Fund, LP

Item 4 is hereby amended to add the following: The Reporting Persons are holders of shares of Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Stock"), of the Issuer, with rights as provided in the Certificate of Designations, Preferences, and Rights of Series A Convertible Preferred Stock of the Issuer (the "Certificate of Designations"). Section 8 of the of the Certificate of Designations, provides that from and after June 29, 2026, each holder of Series A Preferred Stock shall have the right to require that the Issuer redeem all or any portion of the conversion amount of such Holder's Series A Preferred Stock then outstanding, with such redemption to occur on the date which is the one hundred eightieth (180th) day, or the next business day if such date is not a business day, from the date the holder of Series A Preferred Stock gives notice to the Issuer. Any such redemption shall be pursuant to the terms of the Certificate of Designations. On June 30, 2026, the Reporting Persons submitted an optional redemption notice to the Issuer pursuant to Section 8 of the Certificate of Designations for 19,068.833524 shares of Series A Preferred Stock, plus all accrued and unpaid dividends, as well as all shares of Series A Preferred Stock paid as PIK dividends following June 30, 2026, representing the Reporting Persons' entire holdings of Series A Preferred Stock. The redemption date as set forth in the notice is December 28, 2026. Upon …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-02; the filing has the rest

Wynnefield Partners Small Cap Value, L.P. I

Item 4 is hereby amended to add the following: On September 27, 2026, the Wynnefield Reporting Persons entered into a Voting and Support Agreement (the "Support Agreement") with Lifecore, Inc., a Delaware corporation ("Parent"), and the Issuer in connection with the Agreement and Plan of Merger, dated as of September 27, 2026, among Parent, Hazel Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent ("Merger Sub"), and the Issuer (the "Merger Agreement"). The Merger Agreement provides, among other things and subject to its terms and conditions, for the merger of Merger Sub with and into the Issuer, with the Issuer surviving the merger. Pursuant to the Support Agreement, and subject to its terms and conditions, the Wynnefield Reporting Persons agreed to vote their Covered Shares (as defined in the Support Agreement) in favor of the adoption and approval of the Merger Agreement, the merger and the other transactions contemplated by the Merger Agreement, and in favor of certain proposals to adjourn or postpone a meeting of the Issuer's stockholders if necessary to establish a quorum or obtain the required stockholder vote. The Wynnefield Reporting Persons also agreed to vote their Covered Shares against certain competing acquisition proposals and other matters that would reasonably be expected to impede, interfere with or materially and adversely affect the consummation of the merger, and to cause their Covered Shares to be present for purposes …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-29; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Lifecore Biomedical, Inc.

Who owns Lifecore Biomedical, Inc.?

On this page, 4 holders' latest ownership filings report 5% or more of Lifecore Biomedical, Inc.: Legion Partners Asset Management, LLC (17.3%, Schedule 13D/A, filed 2026-09-28), Wynnefield Partners Small Cap Value, L.P. I (14.3%, Schedule 13D/A, filed 2026-09-29), 22NW Fund, LP (6.74%, Schedule 13D/A, filed 2026-07-02) and BlackRock, Inc. (5.4%, Schedule 13G, filed 2026-07-29).

Who are the largest shareholders of Lifecore Biomedical, Inc.?

By the share each holder's latest filing reports, the largest holders of Lifecore Biomedical, Inc. on this page are Legion Partners Asset Management, LLC (17.3%), Wynnefield Partners Small Cap Value, L.P. I (14.3%) and 22NW Fund, LP (6.74%).

When did Legion Partners Asset Management, LLC buy into Lifecore Biomedical, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Legion Partners Asset Management, LLC on this page is the Schedule 13D/A, filed 2026-07-02, reporting 17.1%; its latest, Schedule 13D/A filed 2026-09-28, reports 17.3%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Lifecore Biomedical, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Lifecore Biomedical, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Lifecore Biomedical, Inc. is mentioned again
• Find former Lifecore Biomedical, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes